Avalo Therapeutics, Inc. Common Stock (AVTX)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 33
- Market Cap
- $865M
About Avalo Therapeutics, Inc. Common Stock
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
SentiSense also tracks daily options readings for Avalo Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Avalo Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.